BT-001
AXP000095.1 · Oncolytic virus
- Platform
- vaccinia virus (Copenhagen, TK- RR-)
- Originator
- Transgene; BioInvent International
- Sponsor
- Transgene
Names
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- Copenhagen
- Replication
- conditionally replicating
- Modifications
- J2R (thymidine kinase) and I4L (ribonucleotide reductase) deleted
- Transgenes
- anti-CTLA-4 antibody (4-E03), CSF2
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C179623
Approvals
No regulatory approval recorded.
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07687875 | Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer | Recruiting | Phase 1 | 2026-10-23 | 2028-12-31 | 20 | Rectal Cancer Patients |
| NCT05302050 | A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus | Unknown | 2022-03-07 | 2025-12-01 | 500 | Diabetes Type 2 | |
| NCT05266625 | Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy | Unknown | 2022-02-14 | 2025-11 | 500 | Diabetes Mellitus, Type 2 | |
| NCT05094401 | Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes | Terminated | Phase 3 | 2021-10-04 | 2023-04-01 | 76 | Type2 Diabetes |
| NCT04886388 | Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes | Completed | Phase 3 | 2021-04-22 | 2022-03-09 | 668 | Type 2 Diabetes |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Terminated | Phase 1/2 | 2021-02-25 | 2025-10-22 | 31 | Melanoma; Merkel Cell Carcinoma; Metastatic Cancer; Non Small Cell Lung Cancer; Soft Tissue Sarcoma; Triple Negative Breast Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38170435 | Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes. | Advances in therapy | 2024 | name in abstract: BT-001 |
| PMID 35778834 | Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial. | Clinical cardiology | 2022 | name in abstract: BT-001 |
| PMID 36181554 | Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes. | Diabetes care | 2022 | name in abstract: BT-001 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42979039 | Digital Cognitive Behavioral Therapy Reduces Intensification of Antihyperglycemic Therapy in Patients With Type 2 Diabetes. | AACE endocrinology and diabetes | 2026 | name in abstract: BT-001 |
| PMID 36592462 | In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d. | Annals of internal medicine | 2023 | name in title: BT-001 |
| PMID 35058324 | Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors. | Journal for immunotherapy of cancer | 2022 | name in abstract: BT-001 |
Notes
Also coded TG6030. Armed with the BioInvent anti-CTLA-4 antibody 4-E03 and GM-CSF; phase I/IIa NCT04725331 terminated 2025.
How to cite
BT-001 (AXP000095.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000095.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.